# Forskolin (Coleus forskohlii)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/forskolin-coleus-forskohlii
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Coleus forskohlii diterpene, Makandi, Coleonol, 7beta-acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxy-labd-14-en-11-one, Plectranthus barbatus extract, Garmar root extract

## Overview

Forskolin is a labdane diterpene (C22H34O7, MW 410.5 g/mol) that directly and irreversibly activates adenylyl cyclase across multiple isoforms, bypassing G-protein-coupled receptors to elevate intracellular cyclic AMP (cAMP) and trigger downstream PKA-mediated signaling cascades. Preclinical and small clinical studies suggest benefits in [body composition](/ingredients/condition/weight-management), intraocular pressure reduction, and bronchodilation, though large-scale human trials with robust effect-size data remain limited.

## Health Benefits

- **Adenylyl Cyclase Activation and cAMP Elevation**: Forskolin binds a hydrophobic pocket on adenylyl cyclase catalytic subunits, directly raising intracellular cAMP levels independent of receptor stimulation, which broadly modulates metabolism, lipolysis, cardiac contractility, and immune signaling.
- **Body Composition and Lipolysis**: By elevating cAMP, forskolin activates hormone-sensitive lipase via PKA phosphorylation, promoting triglyceride hydrolysis in adipocytes; a murine high-fat diet model demonstrated reductions in fat cell diameter alongside improved glucose metabolism, though robust human effect-size data are lacking.
- **Bronchodilation and Respiratory Support**: Elevated cAMP promotes smooth [muscle relaxation](/ingredients/condition/sleep) in bronchial airways; inhaled and oral forskolin preparations have been investigated for asthma management, with small studies suggesting comparable efficacy to some standard bronchodilators.
- **Intraocular Pressure Reduction**: Topical and oral forskolin formulations reduce aqueous humor production through cAMP-mediated suppression of ciliary body secretion, making it a candidate adjunct therapy in open-angle glaucoma research.
- **[Antiviral](/ingredients/condition/immune-support) Activity**: In vitro molecular docking studies reveal forskolin inhibits Cathepsin L (docking score −10.37 kcal/mol, binding free energy −8.86 kcal/mol), a cysteine protease required for viral cell entry; reported IC50 values are 62.9–73.1 μg/mL against CoxB4 and HAV, and 99.0–106.0 μg/mL against HSV-1/2 in Vero cell assays.
- **[Cardiovascular](/ingredients/condition/heart-health) Contractility**: cAMP-dependent PKA phosphorylates cardiac troponin I and phospholamban, increasing myocardial contractility and relaxation rate, supporting exploratory use in models of heart failure.
- **Glucose Metabolism Improvement**: Preclinical high-fat diet models indicate forskolin modulates [insulin sensitivity](/ingredients/condition/weight-management) and glucose uptake pathways downstream of cAMP, though human clinical confirmation with statistically powered trials is still required.

## Mechanism of Action

Forskolin's primary mechanism involves direct, receptor-independent activation of adenylyl cyclase (AC), specifically by inserting into a hydrophobic cleft formed at the interface of the C1 and C2 catalytic domains of the enzyme, stabilizing the active conformation and markedly accelerating the conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP allosterically activates protein kinase A (PKA), which phosphorylates a broad array of downstream substrates including hormone-sensitive lipase (HSL), CREB transcription factor, phospholamban, and cardiac contractile proteins, thereby mediating lipolysis, gene transcription, smooth [muscle relaxation](/ingredients/condition/sleep), and myocardial contractility. Secondary [antiviral](/ingredients/condition/immune-support) mechanisms involve competitive inhibition of Cathepsin L, a lysosomal cysteine protease exploited by enveloped viruses for membrane fusion, with hydrogen-bonding and hydrophobic interactions in the enzyme active site (RMSD ~1.87–1.98 Å) that reduce viral infectivity in vitro. Unlike receptor-level agonists, forskolin's direct AC binding allows it to synergize with agents that elevate cAMP through Gs-coupled receptors, producing supra-additive cAMP responses at lower individual concentrations.

## Clinical Summary

Small human studies and case series have examined forskolin (typically as standardized 10–20% root extract, 250 mg twice daily) for effects on [body composition](/ingredients/condition/weight-management), finding inconclusive or modest reductions in body fat percentage without consistent changes in lean mass. Ophthalmic studies using topical or oral formulations have reported reductions in intraocular pressure in glaucoma patients, though sample sizes are generally below 50 participants and blinding methods vary. Asthma-related investigations suggest a bronchodilatory effect comparable to some inhaled agents in pilot studies, but dose standardization and comparison with gold-standard therapies remain inadequately characterized. Overall, the clinical confidence level for most forskolin health claims is low-to-moderate, with the [cardiovascular](/ingredients/condition/heart-health) and [antiviral](/ingredients/condition/immune-support) indications supported only by mechanistic and preclinical data at this time.

## Nutritional Profile

As a purified diterpene compound rather than a whole food, forskolin itself does not contribute meaningful macronutrients or micronutrients to the diet. The whole tuberous root of Coleus forskohlii contains minor amounts of carbohydrates, dietary fiber, and water, alongside labdane diterpenes including deacetylforskolin, 9-deoxyforskolin, 1,9-dideoxyforskolin, forskoditerpenoside C, D, and E, and various labdane diterpene glycosides in addition to the primary compound. Forskolin's bioavailability is constrained by its moderate lipophilicity and molecular complexity (eight chiral centers, five oxidized positions); absorption is enhanced when consumed with dietary fats or formulated with lipid-based delivery systems. Commercial extracts are standardized to 10–20% forskolin by HPLC, ensuring consistent bioactive delivery, whereas crude root powders and aqueous decoctions provide highly variable and generally lower bioactive concentrations.

## Dosage & Preparation

- **Standardized Root Extract (oral capsule/tablet)**: The most common supplement form; standardized to 10–20% forskolin from dried, ground tuberous roots; typical investigational dose is 250 mg of 10% extract (25 mg forskolin) twice daily with meals.
- **Ethanolic/Methanolic Extract**: Soxhlet or ultrasound-assisted extraction with ethanol (yield ~2.59%) or methanol (yield ~2.91%) produces the highest forskolin concentrations; water extraction yields only ~0.18% and is less preferred.
- **Topical Ophthalmic Solution**: 1% forskolin eye drops have been studied for intraocular pressure reduction; compounded formulations require pharmaceutical-grade standardization.
- **Inhaled Aerosol**: Experimental dry-powder or nebulized preparations explored for asthma; not widely commercially available.
- **Traditional Root Decoction**: Dried tuberous roots are boiled in water for oral consumption in Ayurvedic practice; bioavailability from this preparation is lower than solvent extracts due to poor aqueous solubility of the diterpene.
- **Standardization Note**: Reputable commercial products specify % forskolin per serving; consumers should verify third-party certificate of analysis confirming diterpene content and absence of heavy metals.
- **Timing**: Oral extracts are typically taken with food to minimize potential gastrointestinal irritation; no established circadian dosing advantage has been demonstrated.

## Safety & Drug Interactions

At concentrations within typical supplemental ranges (≤125 μg/mL in vitro MNTC equivalent), forskolin exhibits an acceptable short-term safety profile in preclinical models, with dose-dependent cytotoxicity emerging in vitro above 1000 μg/mL (CC50 322.1 μg/mL in Vero cells) and mild cell growth suppression observed between 31.25–125 μg/mL. Clinically, its cAMP-elevating mechanism raises theoretical concerns for interactions with phosphodiesterase inhibitors (e.g., sildenafil, theophylline), beta-agonists, and anticoagulants such as warfarin, as synergistic cAMP elevation or platelet inhibition could amplify pharmacological effects unpredictably. Individuals with bleeding disorders, hypotension, or active cardiovascular disease should use caution, and concurrent use with antihypertensive agents may potentiate [blood pressure](/ingredients/condition/heart-health) lowering due to vascular smooth [muscle relaxation](/ingredients/condition/sleep). Safety data in pregnancy and lactation are absent from published literature, and use during these periods is not recommended; individuals with polycystic kidney disease should avoid forskolin, as cAMP promotes cyst growth in preclinical models.

## Scientific Research

The clinical evidence base for forskolin is predominantly preclinical, consisting of in vitro cell-culture studies and animal models, with only a modest number of small human trials that frequently lack rigorous controls, adequate sample sizes, or published effect-size statistics. In vitro [antiviral](/ingredients/condition/immune-support) assays in Vero cells established cytotoxicity benchmarks (CC50 322.1 μg/mL, MNTC 125 μg/mL) and antiviral IC50 values, but these findings have not been validated in animal infection models or human trials. Animal studies using high-fat diet murine models demonstrate improvements in [glucose metabolism](/ingredients/condition/weight-management) and reduction in adipocyte diameter, but the lack of detailed sample-size reporting and statistical power limits translational confidence. Human investigations in obesity, asthma, glaucoma, and [cardiovascular](/ingredients/condition/heart-health) domains have been conducted, but published trial data with pre-registered protocols, sufficient n, p-values, and standardized effect sizes (e.g., Cohen's d) are sparse, making definitive efficacy conclusions premature.

## Historical & Cultural Context

Coleus forskohlii (known as Makandi or Garmar in Hindi) has been used for centuries in Ayurvedic medicine, the ancient Indian healing system, where its roots were prescribed as a treatment for heart disease, digestive disorders, abdominal colic, respiratory conditions, and skin diseases including psoriasis and eczema. Traditional Ayurvedic texts reference the plant under the Sanskrit name 'Makanda,' and preparations typically involved decocting the fresh or dried root in water or combining it with ghee for enhanced fat-soluble bioactive absorption. The plant also holds culinary significance in parts of India and East Africa, where the tuberous roots are consumed as a pickled vegetable or condiment, providing both nutritional value and low-level phytochemical exposure. Isolation and structural elucidation of the pure diterpene forskolin was accomplished in 1974 by scientists at the Hoechst pharmaceutical company in collaboration with Indian researchers, marking the transition of this traditional botanical into a subject of modern pharmacological investigation.

## Synergistic Combinations

Forskolin demonstrates additive-to-synergistic cAMP elevation when combined with Gs-coupled receptor agonists such as caffeine (via phosphodiesterase inhibition preventing cAMP degradation) or beta-adrenergic compounds, as dual-pathway stimulation produces supra-physiological PKA activation relevant to lipolysis and [thermogenesis](/ingredients/condition/weight-management) stacks. Co-administration with artichoke extract (luteolin-containing), which inhibits phosphodiesterase-4, is a well-documented nutraceutical pairing designed to sustain elevated cAMP by slowing its hydrolysis, amplifying and prolonging the signaling window initiated by forskolin. For metabolic and body-composition applications, forskolin is sometimes combined with green tea catechins (EGCG) and capsaicin, compounds that independently activate sympathomimetic and TRPV1 thermogenic pathways, creating multi-target lipolytic stacks with mechanistically complementary but experimentally under-validated human efficacy.

## Frequently Asked Questions

### What does forskolin actually do in the body?

Forskolin directly activates the enzyme adenylyl cyclase by binding to a hydrophobic pocket between its C1 and C2 catalytic subunits, bypassing normal receptor-level regulation and causing a rapid rise in intracellular cyclic AMP (cAMP). Elevated cAMP then activates protein kinase A (PKA), which phosphorylates downstream targets including hormone-sensitive lipase in fat cells, phospholamban in the heart, and CREB in the nucleus, producing effects ranging from accelerated fat breakdown to smooth muscle relaxation and altered gene transcription.

### Does forskolin work for weight loss?

Forskolin promotes lipolysis in vitro and in animal models by activating hormone-sensitive lipase via cAMP-PKA signaling, and a murine high-fat diet study demonstrated reduced fat cell diameter and improved glucose metabolism. However, human clinical trials have returned inconclusive results—some small studies using 250 mg of 10% standardized extract twice daily showed modest reductions in body fat percentage, but effect sizes were not consistently statistically significant, and no large, well-controlled RCTs have confirmed meaningful weight loss in humans.

### What is the standard dose of forskolin supplements?

The most commonly investigated supplemental dose in human studies is 250 mg of a standardized 10% forskolin extract taken twice daily with meals, delivering 25 mg of pure forskolin per dose (50 mg/day total). Higher-potency extracts standardized to 20% are also available, allowing equivalent forskolin delivery from a smaller capsule volume; consumers should verify HPLC standardization on the product certificate of analysis rather than relying solely on label claims.

### Are there drug interactions with forskolin I should know about?

Forskolin's mechanism of raising cAMP creates clinically relevant interaction risks with phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, theophylline), which also elevate cAMP by preventing its breakdown, potentially producing excessive cardiovascular or bronchial effects. It may also potentiate antihypertensive medications through vascular smooth muscle relaxation, and theoretical platelet inhibition raises caution with anticoagulants such as warfarin or antiplatelet drugs like clopidogrel; anyone on these medications should consult a healthcare provider before using forskolin supplements.

### Is forskolin safe, and are there side effects?

Within typical supplemental dosing ranges, forskolin appears tolerable in short-term preclinical and small human studies, with the in vitro maximum non-toxic concentration established at 125 μg/mL (Vero cells) and a CC50 of 322.1 μg/mL. Potential side effects at clinical doses may include flushing, low blood pressure, increased heart rate, and gastrointestinal upset, while use is contraindicated in pregnancy, lactation, polycystic kidney disease (cAMP accelerates cyst growth), bleeding disorders, and in individuals using blood-pressure-lowering or anticoagulant medications without medical supervision.

### What is the most bioavailable form of forskolin, and does extraction method matter?

Forskolin supplements are typically standardized to 10-20% forskolin content from Coleus forskohlii root extract, with standardized extracts showing superior bioavailability compared to whole plant material. Lipophilic formulations and those combining forskolin with absorption enhancers may improve intestinal uptake, though clinical studies most commonly use the standardized extract form. The specific extraction solvent and standardization percentage can significantly influence the amount of active compound delivered systemically.

### What does clinical research actually show about forskolin's effectiveness?

Human trials demonstrate modest effects on body composition and fat loss, with most studies showing 2-3 kg greater fat loss over 8-12 weeks compared to placebo, though results are inconsistent across studies. Research on cardiovascular function and blood pressure shows potential benefits in some populations, but evidence remains preliminary and not conclusive for most claimed benefits. The quality of evidence is considered moderate for weight management and low-to-moderate for other health claims, with many studies using small sample sizes.

### Who should avoid forskolin supplementation, and is it safe for specific populations?

Forskolin should be avoided by individuals with low blood pressure, certain cardiac conditions, or those taking anticoagulant medications without medical supervision, as cAMP elevation may potentiate these effects. Pregnant and breastfeeding women lack sufficient safety data and should not use forskolin supplements without consulting a healthcare provider. People with active bleeding disorders, upcoming surgery, or those taking blood thinners should exercise particular caution due to potential interaction risks.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*